Celyad OncologyCLYYF 28 EV-to-FCF is -1.34 as of Jun. 26, 2026. GuruFocus rates CLYYF with a GF Score™ of 28/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 333 Biotechnology companies, Celyad Oncology ranks worse than 300300% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Celyad Oncology's Enterprise Value is $10.77 Mil.
Celyad Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.02 Mil. Therefore, Celyad Oncology's EV-to-FCF for today is -1.34.
The historical rank and industry rank for Celyad Oncology's EV-to-FCF or its related term are showing as below:
CLYYF'
s EV-to-FCF Range Over the Past 10 Years
Min: -15.18 Med: -1.5 Max: 1.52
Current: -1.44
During the past 13 years, the highest EV-to-FCF of Celyad Oncology was 1.52. The lowest was -15.18. And the median was -1.50.
CLYYF's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs CLYYF: -1.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Celyad Oncology's PE Ratio (TTM) for today is calculated as:
Celyad Oncology's share price for today is $0.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celyad Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Celyad Oncology EV-to-FCF Related Terms
Celyad Oncology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celyad Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's EV-to-FCF falls into.
Celyad Oncology's current Enterprise Value is $10.77 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celyad Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a EV-to-FCF of -1.34 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Celyad Oncology and its competitors. According to the industry distribution chart, Celyad Oncology ranks #999999 out of 333 companies in the Biotechnology industry.
Is Celyad Oncology's EV-to-FCF too high?
Celyad Oncology's current EV-to-FCF is -1.34. Based on the distribution chart, Celyad Oncology ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #999999 out of 333 companies for EV-to-FCF. This places Celyad Oncology in the lower half of its industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Celyad Oncology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current EV-to-FCF is -1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.25 — trading 66.7% above its estimated fair value. The current EV-to-FCF is -1.34. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current EV-to-FCF is -1.34 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.25 is trading 66.7% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
EV-to-FCF: -1.34
GF Value™: $0.15 vs. price of $0.25 (66.7% above fair value)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
